Pakistan Society for Molecular and Clinical Hematology (PSMH) is determined to uncover the genetic basis of cancers and hematological diseases at an aim to improve patient outcome by cutting-edge translational molecular hematology research and innovative cancer genetic screening approaches.
About Us
Our mission is to uncover the genetic basis of hematological cancers and improving patient outcome by cutting-edge translation molecular hematology and cancer genomics' research.
Services
Pakistan Society for Molecular and Clinical Hematology (PSMH) has been involved in clinical molecular genetics of hematological malignancies since 2002, as manifested by ISI-indexed publications, presentation in international conferences and research awards from international organizations like American Association for Cancer Research (AACR), American Society for Hematology (ASH) and Italian Society for Experimental Hematology (XIES). We have already carried out many studies correlating clinical outcome of leukemia patients with the genetic abnormalities which resulted in establishing many molecular and genetic tests for differential diagnosis, prognostic stratification, drug selection and assessing the efficacy of anti-cancer treatment. We are open to collaborate with other groups to provide services for molecular and genetic testing in hematological malignancies.
Drop by anytime to see our facilities and learn more about our program - you can contact us here.
Our 21st Century Perspective for Hematological Genetic Medicine
Our team of researchers, scientists and clinicians are fully devoted to progress the knowledge related to molecular biology and genetics in diagnosis, prognosis and treatment of hematological diseases like Leukemia, Lymphoma and related clinical manifestations. Our facilities for genetic testing of hematological malignancies for their implication in clinical management are a true manifestation of that. We urge you to join us in this cause.